Abstract PO1-19-01: NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-risk HER2-positive Breast Cancer (HERO)
Year: 2024
Type: conference-abstract
Source: Cancer Research
Authors: Lior Braunstein, Melissa Mitchell, Hanna Bandos, William Sikov, Atif Khan, Peter Chen, Patricia Ganz, Reshma Jagsi, Julia White, Reena Cecchini, Hyejoo Kang, Shannon Puhalla, Kelly Bolton, Eileen Connolly, Erica Stringer-Reasor, Kimberly Gergelis, Thomas Julian, Eleftherios Mamounas, Norman Wolmark
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Pittsburgh, Women & Infants Hospital of Rhode Island, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Emory University, The Ohio State University, Loyola University Chicago, UPMC Hillman Cancer Center, Columbia University Irving Medical Center, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, University of Rochester Medicine, Allegheny Health Network, Orlando Health, NSABP Foundation
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4396598649